ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Mar 7, 2012-- nanoMR, an emerging life sciences company that develops real-time, ultra-sensitive diagnostic systems for blood pathogen detection, today announced the appointment of Jim Macemon as vice president, product development. In his new position, Macemon will coordinate the efforts of nanoMR's internal development team with several external development and manufacturing partners. Specifically, he will oversee the design and manufacture of disposable cassettes for the company's Pathogen Capture System for the blood culture market, as well as the medical device that will activate them.
nanoMR's Pathogen Capture System recovers microbial cells directly from drawn blood and delivers purified microbial DNA in less than one hour. The system uses immunomagnetic technology to rapidly isolate bacteria and fungi from bloodstream infections or specific cell types, including circulating tumor and fetal cells, in less than 30 minutes.
Using conventional methods such as Polymerase Chain Reaction (PCR), the causative agents can be identified in less than two hours, making it possible for physicians to begin the appropriate patient therapy in suspected cases of bloodstream infection.
Macemon brings more than 30 years of medical device development and manufacturing experience to his new post. For 15 years prior to joining nanoMR, he worked with venture capital-funded start-up companies to develop new diagnostic and imaging technology. Most recently, Macemon was vice president, operations at Luminous Medical, where he led development, manufacturing and quality teams that created a real-time monitor for measuring glucose in whole blood. Macemon has also held senior positions at Baxter Healthcare, Richardson-Vicks and SpaceLabs Medical, where he oversaw the development of programs for laboratory and point-of-care diagnostic systems. He holds 13 patents and has several more pending.
"The depth of Jim's medical device development and manufacturing experience in diagnostics, critical care, patient monitoring, imaging and laboratory products is an ideal fit for the work we are doing at nanoMR," said Victor Esch, Ph.D., nanoMR president and CEO. "He will play a critical role as we prepare to begin clinical trials for our Pathogen Capture System in Europe within the next year." About nanoMR Founded in 2007 by renowned researchers from the University of New Mexico, nanoMR is an early stage life sciences company that develops novel diagnostic systems for the rapid, ultrasensitive detection of pathogens in whole blood and other samples. nanoMR's systems couple immunochemistry with patented nuclear magnetic resonance (NMR) technology to produce small, simple, inexpensive devices that offer unparalleled speed and sensitivity. The company's first product addresses the blood culture market, demonstrating detection of blood-borne infections in less than two hours, compared with days required for conventional blood culture systems. For more information, visit www.nanomr.com.
CONTACT: Mather Communications Ellen Mather, 505-410-7255 email@example.com or nanoMR Victor Esch, 505-924-6301 President & CEO firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA NEW MEXICO INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS MEDICAL DEVICES GENERAL HEALTH SOURCE: nanoMR Copyright Business Wire 2012 PUB: 03/07/2012 09:01 AM/DISC: 03/07/2012 09:01 AM http://www.businesswire.com/news/home/20120307005157/